Determination of parathyroid hormone: from radioimmunoassay to LCMS/MS.
mass spectrometry
parathormone
reference range
review
stability
standardisation
vitamin D
Journal
Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306
Informations de publication
Date de publication:
25 04 2023
25 04 2023
Historique:
received:
21
09
2022
accepted:
05
01
2023
medline:
3
4
2023
pubmed:
15
1
2023
entrez:
14
1
2023
Statut:
epublish
Résumé
Parathyroid hormone (PTH) determination is of paramount importance for the exploration of diseases related with calcium metabolism and for the follow-up of patients suffering from bone and mineral disorders associated with chronic kidney diseases (CKD-MBD). Unfortunately, the biologically active form of PTH, i.e. 1-84 PTH, circulates in the blood stream with many fragments and post-translationally modified forms, which decreases the specificity of immunoassays. The assays used to measure PTH, either from 2nd or 3rd generation, are not standardised, which may lead to interpretation errors and clinical consequences. Reference ranges for PTH have neither been always correctly established and the stability of the peptide is also a matter of concern. Fortunately, these last years, newer techniques using mass spectrometry (either high resolution or triple quadripole) coupled with liquid chromatography have been developed, which will help to standardise the different assays. Indeed, PTH assays standardisation is one of the task of the IFCC Committee for Bone Metabolism. Such standardisation will allow a better consistency in the interpretation of the results and will promote studies aiming at the establishment of correct reference ranges.
Identifiants
pubmed: 36640443
pii: cclm-2022-0942
doi: 10.1515/cclm-2022-0942
doi:
Substances chimiques
Parathyroid Hormone
0
Peptides
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
946-953Informations de copyright
© 2023 Walter de Gruyter GmbH, Berlin/Boston.
Références
Ramasamy, I. Inherited disorders of calcium homeostasis. Clin Chim Acta 2008;394:22–41. https://doi.org/10.1016/J.CCA.2008.04.011 .
doi: 10.1016/J.CCA.2008.04.011
Jüppner, H, Abou-Samra, AB, Freeman, M, Kong, XF, Schipani, E, Richards, J, et al.. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 1991;254:1024–6. https://doi.org/10.1126/SCIENCE.1658941 .
doi: 10.1126/SCIENCE.1658941
Gardella, TJ, Axelrod, D, Rubin, D, Keutmann, HT, Potts, JT, Kronenberg, HM, et al.. Mutational analysis of the receptor-activating region of human parathyroid hormone. J Biol Chem 1991;266:13141–6. https://doi.org/10.1016/s0021-9258(18)98816-2 .
doi: 10.1016/s0021-9258(18)98816-2
Pfister, MF, Ruf, I, Stange, G, Ziegler, U, Lederer, E, Biber, J, et al.. Parathyroid hormone leads to the lysosomal degradation of the renal type II Na/Pi cotransporter. Proc Natl Acad Sci 1998;95:1909–14. https://doi.org/10.1073/pnas.95.4.1909 .
doi: 10.1073/pnas.95.4.1909
Naylor, SL, Sakaguchi, AY, Szoka, P, Hendy, GN, Kronenberg, HM, Rich, A, et al.. Human parathyroid hormone gene (PTH) is on short arm of chromosome 11. Somat Cell Genet 1983;9:609–16. https://doi.org/10.1007/bf01574261 .
doi: 10.1007/bf01574261
Habener, JF, Rosenblatt, M, Kemper, B, Kronenberg, HM, Rich, A, Potts, JT. Pre-proparathyroid hormone; amino acid sequence, chemical synthesis, and some biological studies of the precursor region. Proc Natl Acad Sci USA 1978;75:2616–20. https://doi.org/10.1073/pnas.75.6.2616 .
doi: 10.1073/pnas.75.6.2616
Arnold, A, Horst, SA, Gardella, TJ, Baba, H, Levine, MA, Kronenberg, HM. Mutation of the signal peptide-encoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism. J Clin Invest 1990;86:1084–7. https://doi.org/10.1172/JCI114811 .
doi: 10.1172/JCI114811
Segre, GV, Perkins, AS, Witters, L, Potts, JT. Metabolism of parathyroid hormone by isolated rat kupffer cells and hepatocytes. J Clin Invest 1981;67:449–57. https://doi.org/10.1172/jci110053 .
doi: 10.1172/jci110053
Yamashita, H, Gao, P, Cantor, T, Futata, T, Murakami, T, Uchino, S, et al.. Large carboxy-terminal parathyroid hormone (PTH) fragment with a relatively longer half-life than 1-84 PTH is secreted directly from the parathyroid gland in humans. Eur J Endocrinol 2003;149:301–6. https://doi.org/10.1530/eje.0.1490301 .
doi: 10.1530/eje.0.1490301
D’amour, P, Lazure, C, Labelle, F. Metabolism of radioiodinated carboxy-terminal fragments of bovine parathyroid hormone in normal and anephric rats. Endocrinology 1985;117:127–34. https://doi.org/10.1210/endo-117-1-127 .
doi: 10.1210/endo-117-1-127
Kritmetapak, K, Losbanos, LA, Hines, JM, O’Grady, KL, Ulmer, CZ, Vesper, HW, et al.. Chemical characterization and quantification of circulating intact PTH and PTH fragments by high-resolution mass spectrometry in chronic renal failure. Clin Chem 2021;67:843–53. https://doi.org/10.1093/clinchem/hvab013 .
doi: 10.1093/clinchem/hvab013
Singh, RJ, Hines, JM, Lopez, MF, Krastins, B, Hoofnagle, a. N. Mass spectrometric immunoassay raises doubt for the existence of parathyroid hormone fragment 7–84. Clin Chem 2015;61:558–60. https://doi.org/10.1373/clinchem.2014.235440 .
doi: 10.1373/clinchem.2014.235440
Farré-Segura, J, Le Goff, C, Lukas, P, Cobraiville, G, Fillet, M, Servais, AC, et al.. Validation of an LC-MS/MS method using solid-phase extraction for the quanti fi cation of 1-84 parathyroid hormone : toward a candidate reference measurement procedure. Clin Chem 2022;68:1399–409.
Sneddon, WB, Magyar, CE, Willick, GE, Syme, CA, Galbiati, F, Bisello, A, et al.. Ligand-selective dissociation of activation and internalization of the parathyroid hormone (PTH) receptor: conditional efficacy of PTH peptide fragments. Endocrinology 2004;145:2815–23. https://doi.org/10.1210/en.2003-1185 .
doi: 10.1210/en.2003-1185
Slatopolsky, E, Finch, J, Clay, P, Martin, D, Sicard, G, Singer, G, et al.. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000;58:753–61. https://doi.org/10.1046/j.1523-1755.2000.00222.x .
doi: 10.1046/j.1523-1755.2000.00222.x
Divieti, P, Inomata, N, Chapin, K, Singh, R, Jüppner, H, Bringhurst, FR. Receptors for the carboxyl-terminal region of PTH(1-84) are highly expressed in osteocytic cells. Endocrinology 2001;142:916–25. https://doi.org/10.1210/en.142.2.916 .
doi: 10.1210/en.142.2.916
Divieti, P, John, MR, Jüppner, H, Bringhurst, FR. Human PTH- ( 7–84 ) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 2002;143:171–6. https://doi.org/10.1210/endo.143.1.8575 .
doi: 10.1210/endo.143.1.8575
Kukreja, SC, D’Anza, JJ, Wimbiscus, SA, Fisher, JE, McKee, RL, Caulfield, MP, et al.. Inactivation by plasma may be responsible for lack of efficacy of parathyroid hormone antagonists in hypercalcemia of malignancy. Endocrinology 1994;134:2184–8. https://doi.org/10.1210/endo.134.5.8156920 .
doi: 10.1210/endo.134.5.8156920
Murray, TM, Rao, LG, Muzaffar, SA, Ly, H. Human parathyroid hormone carboxyterminal peptide (53–84) stimulates alkaline phosphatase activity in dexamethasone-treated rat osteosarcoma cells in vitro. Endocrinology 1989;124:1097–9. https://doi.org/10.1210/endo-124-2-1097 .
doi: 10.1210/endo-124-2-1097
Sutherland, MK, Rao, LG, Wylie, JN, Gupta, A, Ly, H, Sodek, J, et al.. Carboxyl-terminal parathyroid hormone peptide (53–84) elevates alkaline phosphatase and osteocalcin mRNA levels in SaOS-2 cells. J Bone Miner Res 2009;9:453–8. https://doi.org/10.1002/jbmr.5650090403 .
doi: 10.1002/jbmr.5650090403
Lippi, G, Guidi, GC, Mattiuzzi, C, Plebani, M. Preanalytical variability: the dark side of the moon in laboratory testing. Clin Chem Lab Med 2006;44:358–65. https://doi.org/10.1515/CCLM.2006.073 .
doi: 10.1515/CCLM.2006.073
Lippi, G, Blanckaert, N, Bonini, P, Green, S, Kitchen, S, Palicka, V, et al.. Causes, consequences, detection, and prevention of identification errors in laboratory diagnostics. Clin Chem Lab Med 2009;47:143–53. https://doi.org/10.1515/CCLM.2009.045 .
doi: 10.1515/CCLM.2009.045
Lippi, G, Becan-McBride, K, Behúlová, D, Bowen, RA, Church, S, Delanghe, J, et al.. Preanalytical quality improvement: in quality we trust. Clin Chem Lab Med 2013;51:229–41. https://doi.org/10.1515/CCLM-2012-0597 .
doi: 10.1515/CCLM-2012-0597
Lippi, G, Banfi, G, Church, S, Cornes, M, De Carli, G, Grankvist, K, et al.. Preanalytical quality improvement. In pursuit of harmony, on behalf of European federation for clinical Chemistry and laboratory medicine (EFLM) working group for preanalytical phase (WG-PRE). Clin Chem Lab Med 2015;53:357–70. https://doi.org/10.1515/CCLM-2014-1051 .
doi: 10.1515/CCLM-2014-1051
Cavalier, E, Plebani, M, Delanaye, P, Souberbielle, J-C. Considerations in parathyroid hormone testing. Clin Chem Lab Med 2015;53:1913–9. https://doi.org/10.1515/cclm-2015-0314 .
doi: 10.1515/cclm-2015-0314
Hanon, EA, Sturgeon, CM, Lamb, EJ. Sampling and storage conditions influencing the measurement of parathyroid hormone in blood samples: a systematic review. Clin Chem Lab Med 2013;51:1925–41. https://doi.org/10.1515/cclm-2013-0315 .
doi: 10.1515/cclm-2013-0315
Valcour, A, Zierold, C, Blocki, FA, Hawkins, DM, Martin, KJ, Rao, SD, et al.. Trueness, precision and stability of the LIAISON 1–84 parathyroid hormone (PTH) third-generation assay: comparison to existing intact PTH assays. Clin Chem Lab Med 2018;56:1476–82. https://doi.org/10.1515/cclm-2018-0217 .
doi: 10.1515/cclm-2018-0217
ISO Guide 5725-6:1994 . Accuracy (trueness and precision) of measurement methods and results — part 6: use in practice of accuracy values ; n.d.
World Health Organization . Use of anticoagulants in diagnostic laboratory investigations ; 2002.
Schleck, ML, Souberbielle, JC, Delanaye, P, Plebani, M, Cavalier, E. Parathormone stability in hemodialyzed patients and healthy subjects: comparison on non-centrifuged EDTA and serum samples with second- and third-generation assays. Clin Chem Lab Med 2017;55:1152–9. https://doi.org/10.1515/cclm-2016-0914 .
doi: 10.1515/cclm-2016-0914
Cavalier, E, Carlisi, A, Bekaert, AC, Rousselle, O, Chapelle, JP, Delanaye, P. New insights on the stability of the parathyroid hormone as assayed by an automated 3rd generation PTH assay. Clin Chim Acta 2012;413:353–4. https://doi.org/10.1016/j.cca.2011.09.034 .
doi: 10.1016/j.cca.2011.09.034
Cavalier, E, Delanaye, P, Hubert, P, Krzesinski, JM, Chapelle, JP, Rozet, E. Estimation of the stability of parathyroid hormone when stored at −80°C for a long period. Clin J Am Soc Nephrol 2009;4:1988–92. https://doi.org/10.2215/CJN.03970609 .
doi: 10.2215/CJN.03970609
Cavalier, E, Delanaye, P, Carlisi, A, Krzesinski, JM, Chapelle, JP. Stability of intact parathyroid hormone in samples from hemodialysis patients. Kidney Int 2007;72:370–2. https://doi.org/10.1038/sj.ki.5002363 .
doi: 10.1038/sj.ki.5002363
Vulpio, C, Bossola, M, Speranza, D, Zuppi, C, Luciani, G, Di Stasio, E. Influence of blood sampling site on intact parathyroid hormone concentrations in hemodialysis patients. Clin Chem 2010;56:489–90. https://doi.org/10.1373/clinchem.2009.136754 .
doi: 10.1373/clinchem.2009.136754
Morris, HA, Eastell, R, Jorgensen, NR, Cavalier, E, Vasikaran, S, Chubb, SAP, et al.. IFCC-IOF working group for standardisation of bone marker assays (WG-BMA), clinical usefulness of bone turnover marker concentrations in osteoporosis. Clin Chim Acta 2017;467:34–41. https://doi.org/10.1016/j.cca.2016.06.036 .
doi: 10.1016/j.cca.2016.06.036
Ginsberg, C, Miller, LM, Ofsthun, N, Dalrymple, LS, Ix, JH. Differences in phosphate and parathyroid hormone concentrations over the day among patients on hemodialysis. J Am Soc Nephrol 2022;33:2087–93. https://doi.org/10.1681/ASN.2021111493 .
doi: 10.1681/ASN.2021111493
Samuels, MH, Veldhuis, JD, Kramer, P, Urban, RJ, Bauer, R, Mundy, GR. Episodic secretion of parathyroid hormone in postmenopausal women: assessment by deconvolution analysis and approximate entropy. J Bone Miner Res 1997;12:616–23. https://doi.org/10.1359/jbmr.1997.12.4.616 .
doi: 10.1359/jbmr.1997.12.4.616
Cavalier, E, Delanaye, P, Moranne, O. Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am J Kidney Dis 2013;61:847–8. https://doi.org/10.1053/j.ajkd.2012.12.013 .
doi: 10.1053/j.ajkd.2012.12.013
Bottani, M, Banfi, G, Guerra, E, Locatelli, M, Aarsand, AK, Coşkun, A, et al.. European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates for serum biointact parathyroid hormone based on weekly samplings from 91 healthy participants. Ann Transl Med 2020;8:855. https://doi.org/10.21037/ATM-19-4498 .
doi: 10.21037/ATM-19-4498
Guillemant, J, Cabrol, S, Allemandou, A, Peres, G, Guillemant, S. Vitamin D-dependent seasonal variation in growing male adolescents. Bone 1995;17:513–6. https://doi.org/10.1016/8756-3282(95)00401-7 .
doi: 10.1016/8756-3282(95)00401-7
Nevo-Shor, A, Kogan, S, Joshua, BZ, Bahat-Dinur, A, Novack, V, Fraenkel, M. Seasonal changes in serum calcium, PTH and vitamin D levels in patients with primary hyperparathyroidism. Bone 2016;89:59–63. https://doi.org/10.1016/j.bone.2016.05.012 .
doi: 10.1016/j.bone.2016.05.012
Cong, E, Walker, MD, Kepley, A, Zhang, C, McMahon, DJ, Silverberg, SJ. Seasonal variability in vitamin D levels No longer detectable in primary hyperparathyroidism. J Clin Endocrinol Metab 2015;100:3452–9. https://doi.org/10.1210/JC.2015-2105 .
doi: 10.1210/JC.2015-2105
Bilezikian, JP, Brandi, ML, Eastell, R, Silverberg, SJ, Udelsman, R, Marcocci, C, et al.. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocrinol Metab 2014;99:3561–9. https://doi.org/10.1210/jc.2014-1413 .
doi: 10.1210/jc.2014-1413
Berson, SA, Yalow, RS, Aurbach, GD, Potts, JT. Immunoassay of bovine and human parathyroid hormone. Proc Natl Acad Sci 1963;49:613–7. https://doi.org/10.1073/pnas.49.5.613 .
doi: 10.1073/pnas.49.5.613
Nussbaum, SR, Zahradnik, RJ, Lavigne, JR, Brennan, GL, Nozawa-Ung, K, Kim, LY, et al.. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987;33:1364–7. https://doi.org/10.1093/clinchem/33.8.1364 .
doi: 10.1093/clinchem/33.8.1364
Quarles, LD, Lobaugh, B, Murphy, G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992;75:145–50. https://doi.org/10.1210/jcem.75.1.1619003 .
doi: 10.1210/jcem.75.1.1619003
Wang, M, Hercz, G, Sherrard, DJ, Maloney, NA, Segre, GV, Pei, Y. Relationship between intact 1–84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995;26:836–44. https://doi.org/10.1016/0272-6386(95)90453-0 .
doi: 10.1016/0272-6386(95)90453-0
Lepage, R, Roy, L, Brossard, JH, Rousseau, L, Dorais, C, Lazure, C, et al.. A non-(1–84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998;44:805–9. https://doi.org/10.1093/clinchem/44.4.805 .
doi: 10.1093/clinchem/44.4.805
John, MR, Goodman, WG, Ping, G, Cantor, T, Salusky, IB, Juppner, H. A Novel Immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999;84:4287–90. https://doi.org/10.1210/jcem.84.11.6236 .
doi: 10.1210/jcem.84.11.6236
Sturgeon, CM, Sprague, S, Almond, A, Cavalier, E, Fraser, WD, Algeciras-Schimnich, A, et al.. Perspective and priorities for improvement of parathyroid hormone (PTH) measurement – a view from the IFCC Working Group for PTH. Clin Chim Acta 2017;467:42–7. https://doi.org/10.1016/j.cca.2016.10.016 .
doi: 10.1016/j.cca.2016.10.016
Kumar, V, Barnidge, DR, Chen, LS, Twentyman, JM, Cradic, KW, Grebe, SK, et al.. Quantification of serum 1–84 parathyroid hormone in patients with hyperparathyroidism by immunocapture in situ digestion liquid chromatography-tandem mass spectrometry. Clin Chem 2010;56:306–13. https://doi.org/10.1373/clinchem.2009.134643 .
doi: 10.1373/clinchem.2009.134643
Lopez, MF, Rezai, T, Sarracino, DA, Prakash, A, Krastins, B, Athanas, M, et al.. Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin Chem 2010;56:281–90. https://doi.org/10.1373/clinchem.2009.137323 .
doi: 10.1373/clinchem.2009.137323
Rubin, MR, Silverberg, SJ, D’Amour, P, Brossard, JH, Rousseau, L, Sliney, J, et al.. An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1–84) is overproduced in parathyroid carcinoma. Clin Chem 2007;53:1470–6. https://doi.org/10.1373/clinchem.2007.085506 .
doi: 10.1373/clinchem.2007.085506
Cavalier, E, Daly, AF, Betea, D, Pruteanu-Apetrii, PN, Delanaye, P, Stubbs, P, et al.. The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab 2010;95:3745–9. https://doi.org/10.1210/jc.2009-2791 .
doi: 10.1210/jc.2009-2791
Räkel, A, Brossard, JH, Patenaude, JV, Albert, C, Nassif, E, Cantor, T, et al.. Overproduction of an amino-terminal form of PTH distinct from human PTH(1–84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery. Clin Endocrinol 2005;62:721–7. https://doi.org/10.1111/j.1365-2265.2005.02286.x .
doi: 10.1111/j.1365-2265.2005.02286.x
Souberbielle, JC, Friedlander, G, Cormier, C. Practical considerations in PTH testing. Clin Chim Acta 2006;366:81–9. https://doi.org/10.1016/j.cca.2005.10.010 .
doi: 10.1016/j.cca.2005.10.010
D’Amour, P, Brossard, JH, Rousseau, L, Roy, L, Gao, P, Cantor, T. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1–84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 2003;49:2037–44. https://doi.org/10.1373/clinchem.2003.021592 .
doi: 10.1373/clinchem.2003.021592
Schulte, KM, Talat, N. Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol 2012;8:612–22. https://doi.org/10.1038/nrendo.2012.102 .
doi: 10.1038/nrendo.2012.102
Caron, P, Maiza, JC, Renaud, C, Cormier, C, Barres, BH, Souberbielle, JC. High 3rd generation/2nd generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of 3rg generation/2nd generation PTH ratio in patients with primary hyperparathyroidism. Clin Endocrinol 2008;70:533–8. https://doi.org/10.1111/j.1365-2265.2008.03408.x .
doi: 10.1111/j.1365-2265.2008.03408.x
Hocher, B, Yin, L. Why current PTH assays mislead clinical decision making in patients with secondary hyperparathyroidism. Nephron 2017;136:137–42. https://doi.org/10.1159/000455289 .
doi: 10.1159/000455289
Himmelfarb, J, Stenvinkel, P, Ikizler, TA, Hakim, RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524–38. https://doi.org/10.1046/J.1523-1755.2002.00600.X .
doi: 10.1046/J.1523-1755.2002.00600.X
Hocher, B, Armbruster, FP, Stoeva, S, Reichetzeder, C, Grön, HJ, Lieker, I, et al.. Measuring parathyroid hormone (PTH) in patients with oxidative stress – do we need a fourth generation parathyroid hormone assay? PLoS One 2012;7:e40242. https://doi.org/10.1371/journal.pone.0040242 .
doi: 10.1371/journal.pone.0040242
Lu, YP, Zeng, S, Chu, C, Hasan, AA, Slowinski, T, Yin, LH, et al.. Non-oxidized PTH (n-oxPTH) is associated with graft loss in kidney transplant recipients. Clin Chim Acta 2020;508:92–7. https://doi.org/10.1016/J.CCA.2020.05.022 .
doi: 10.1016/J.CCA.2020.05.022
Hocher, B, Zeng, S. Need for better PTH assays for clinical research and patient treatment. Clin Chem Lab Med 2017;56:13–5. https://doi.org/10.1515/cclm-2017-0617 .
doi: 10.1515/cclm-2017-0617
Seiler-Mussler, S, Limbach, AS, Emrich, IE, Pickering, JW, Roth, HJ, Fliser, D, et al.. Association of nonoxidized parathyroid hormone with cardiovascular and kidney disease outcomes in chronic kidney disease. Clin J Am Soc Nephrol 2018;13:569–76. https://doi.org/10.2215/CJN.06620617 .
doi: 10.2215/CJN.06620617
Ursem, SR, Heijboer, AC, D’Haese, PC, Behets, GJ, Cavalier, E, Vervloet, MG, et al.. Non-oxidized parathyroid hormone (PTH) measured by current method is not superior to total PTH in assessing bone turnover in chronic kidney disease. Kidney Int 2021;99:1173–8. https://doi.org/10.1016/j.kint.2020.12.024 .
doi: 10.1016/j.kint.2020.12.024
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis . Evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2017;7:1–59. https://doi.org/10.1016/j.kisu.2017.04.001 .
doi: 10.1016/j.kisu.2017.04.001
Touvier, M, Deschasaux, M, Montourcy, M, Sutton, A, Charnaux, N, Kesse-Guyot, E, et al.. Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: importance of the reference values. J Clin Endocrinol Metab 2014;99:1196–203. https://doi.org/10.1210/jc.2013-3349 .
doi: 10.1210/jc.2013-3349
Souberbielle, JC, Fayol, V, Sault, C, Lawson-Body, E, Kahan, A, Cormier, C. Assay-specific decision limits for two new automated parathyroid hormone and 25-hydroxyvitamin D assays. Clin Chem 2005;51:395–400. https://doi.org/10.1373/clinchem.2004.037606 .
doi: 10.1373/clinchem.2004.037606
Cavalier, E, Delanaye, P, Vranken, L, Bekaert, AC, Carlisi, A, Chapelle, JP, et al.. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol Dial Transplant 2011;27:1950–6. https://doi.org/10.1093/ndt/gfr535 .
doi: 10.1093/ndt/gfr535
Moe, SM, Drueke, TB. For the K.W. Group, KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease mineral and bone disorder (CKD-MBD). Kidney Int 2009;76:S1–28. https://doi.org/10.1038/ki.2009.188 .
doi: 10.1038/ki.2009.188